Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo.

Antimicrobial agents and chemotherapy - 1 Jan 2002

Walter Hauke, Schmidt Barbara, Werwein Marianne, Schwingel Eva, Korn Klaus

Abstract excerpt

Abacavir is frequently used in antiretroviral combination therapies as a potent nucleoside reverse transcriptase inhibitor (NRTI). Four mutations are selected for by abacavir in vitro and in vivo: K65R, L74V, Y115F, and M184V. Abacavir resistance has also been observed in NRTI multidrug-resistant samples. Furthermore, abacavir resistance has been described in the context of zidovudine resistance. To evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dideoxynucleosides

Share to Drug Resistance, Microbial

Share to Lamivudine

Share to Microbial Sensitivity Tests

Share to Zidovudine

Source

Open in PubMed Open full text

Identifiers

PMID: 11751116
DOI: 10.1128/AAC.46.1.89-94.2002
PMCID: PMC126991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo.PMID 11751116Read ↗

Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.Semantic proximity Read ↗

Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance.Semantic proximity Read ↗

Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.Semantic proximity Read ↗

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.Semantic proximity Read ↗

Clinically relevant interpretation of genotype for resistance to abacavir.Semantic proximity Read ↗

Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype.Semantic proximity Read ↗

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.Semantic proximity Read ↗

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.Semantic proximity Read ↗

Association of antiretroviral resistance genotypes with response to therapy--comparison of three models.Semantic proximity Read ↗

The impact of the M184V substitution on drug resistance and viral fitness.Semantic proximity Read ↗

Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response.Semantic proximity Read ↗

Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.